SGLT2 Inhibitor Cancer Risk Meta-Analysis: 28 Trials and 98,297 Participants

28 randomized controlled trials involving 98,297 participants form the basis of this systematic review on the cancer risk of SGLT2 inhibitors. The meta-analysis, registered as CRD42024560310, found no significant increase in overall cancer risk (RR=1.05) or in several common cancer types. Author Jing Teng published the results on figshare in May 2026.

Use Cases

• Assessing the association between SGLT2 inhibitors and overall cancer risk based on pooled risk ratios from 28 trials.
• Evaluating drug safety for specific patient populations like those with heart failure or chronic kidney disease based on subgroup analyses.
• Comparing cancer risk profiles across different types of SGLT2 inhibitors as mentioned in the results.

Strengths

• Analysis is based on 28 randomized controlled trials, a substantial number for a meta-analysis.
• Includes data from 98,297 participants, providing a large sample size for safety evaluation.
• The study protocol was pre-registered in PROSPERO (CRD42024560310), indicating structured methodology.

Limitations

• The dataset is a 53.5 KB DOCX file, suggesting limited raw data and likely consisting of summary tables or a manuscript.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for quantitative reuse.

Provenance

Source

figshare

Collection Method

Systematic review and meta-analysis of studies from PubMed, CENTRAL, Web of Science, and ClinicalTrials.gov up to April 16, 2024.

Time Range

Studies published up to April 16, 2024.

Freshness

Last updated 2026-05-08 05:57:08; freshness should be verified.